Showing 2051-2060 of 5696 results for "".
- Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with J&J’s Janssenhttps://modernod.com/news/morphic-therapeutic-enters-into-integrin-research-and-development-collaboration-with-jjs-janssen/2476272/Morphic Therapeutic announced that it has entered into a research and development collaboration with Johnson & Johnson’s subsidiary Janssen Biotech, to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies. Johnson &a
- Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulationshttps://modernod.com/news/melt-pharmaceuticals-improves-patent-estate-for-sublingual-non-opioid-pain-and-sedation-formulations/2476298/Melt Pharmaceuticals, a specialty pharmaceutical company recently deconsolidated from Harrow Health, announced the U.S. Patent and Trademark office has issued two additional patents covering the company’s innovative sublingual, non-opioid pain and sedation formulations. U.S. Patents 10,16
- Tangible Science Introduces Lens Care System for Custom Contact Lenses Coated with Tangible Hydra-PEGhttps://modernod.com/news/tangible-science-introduces-lens-care-system-for-custom-contact-lenses-coated-with-tangible-hydra-peg/2479600/Tangible Science will be unveiling at the Global Specialty Lens Symposium this week its complete system of products designed to ensure that custom contact lenses coated with Tangible Hydra-PEG offer benefit for the prescribed life of the lenses. Tangible Hydra-PEG is a unique polymer coati
- Aerie Pharmaceuticals Announces Acceptance of Its Investigational NDA for AR-1105 (Dexamethasone Intravitreal Implant)https://modernod.com/news/aerie-pharmaceuticals-announces-acceptance-of-its-investigational-nda-for-ar-1105-dexamethasone-intravitreal-implant/2476183/Aerie Pharmaceuticals announced that the FDA has reviewed the investigational new drug application (IND) for AR-1105 (dexamethasone intravitreal implant) and it is now in effect, allowing Aerie to initiate human studies in the treatment of macular edema due to retinal vein occlusion (RVO). The IN
- ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10https://modernod.com/news/proqr-reaches-agreement-with-the-fda-on-design-of-phase-2-3-pivotal-trial-for-sepofarsen-qr-110-for-lebers-congenital-amaurosis-10/2476214/ProQR Therapeutics announced that it has reached agreement with the FDA on the design of a phase 2/3 pivotal trial (ILLUMINATE) for QR-110, now renamed to sepofarsen, in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290gene. LCA is the lead
- Oculis Raises $15.7 Million to Advance Development of Novel Topical Treatments for Ophthalmic Diseaseshttps://modernod.com/news/oculis-raises-15-7-million-to-advance-development-of-novel-topical-treatments-for-ophthalmic-diseases/2476221/Oculis announced that it has successfully raised a further 15.5 million Swiss Franc ($15.7 million) in an extension of its Series B financing round, announced in January 2018, bringing the total raised to 35.5 million Swiss Franc. The extension round was led by funds managed by Tekla Capital Mana
- ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2https://modernod.com/news/proqr-receives-fast-track-designation-from-fda-for-qr-421a-for-usher-syndrome-type-2/2476227/ProQR Therapeutics announced that it received Fast Track designation from the FDA for QR-421a, a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) d
- Beaver-Visitec International to Acquire PhysIOL Grouphttps://modernod.com/news/tpg-capital-backs-bvi-to-acquire-physiol-group-sa/2476246/Beaver-Visitec International (BVI) announced it has signed a definitive agreement to acquire PhysIOL Group, a Belgium-based ophthalmic company specializing in the research, development, and manufacture of IOLs, from TA Associates. Financial terms of the transaction were not disclosed.
- Notal Vision Engages Wasatch Photonics Bringing AI-Enabled Home-Based OCT Closer to Markethttps://modernod.com/news/notal-vision-engages-wasatch-photonics-bringing-ai-enabled-home-based-oct-closer-to-market/2479605/Notal Vision has announced the achievement of a significant milestone in its plan to develop and commercialize a home-based, patient-operated, spectral-domain optical coherence tomography (SD-OCT) system. The first targeted application of the Notal Home OCT is to monitor wet age-related macular d
- FDA Clears First Daily Disposable Silicone Hydrogel Contact Lens Coated with Modified Formula of Tangible Hydra-PEGhttps://modernod.com/news/fda-clears-first-daily-disposable-silicone-hydrogel-contact-lens-coated-with-modified-formula-of-tangible-hydra-peg/2479611/Tangible Science announced that the FDA has cleared the first daily disposable silicone hydrogel contact lens coated with a modified formula of Tangible Hydra-PEG. Tangible Hydra-PEG is an innovative coating applied to custom contact lenses to improve lens wettability and deposit resistanc